Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Moyer

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Chesterland, OH Clinical Nurse Specialist

NPI 1902120173 CMS profile 10832936

8211 Mayfield Rd, Chesterland, OH 44026

Open in the dashboard

General payments

$4,375

264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Moyer of Chesterland, OH is reported in the CMS Open Payments database as having received $4,375 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $522 29
2024 General $1,390 79
2023 General $1,209 72
2022 General $675 42
2021 General $579 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Moyer
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Laura Moyer were reported at $522. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Laura Moyer Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $579 $152 $38–$472 $132
2022 $675 $172 $73–$546 $149
2023 $1,209 $156 $56–$560 $160
2024 $1,390 $158 $39–$521 $164
2025 $522 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $745 51 payments
  2. Lundbeck LLC $669 36 payments
  3. AbbVie, Inc. $424 26 payments
  4. ITI, Inc. $417 28 payments
  5. Corium, Inc. $345 21 payments
  6. Axsome Therapeutics, Inc. $306 15 payments
  7. Alkermes, Inc. $303 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $243 14 payments
  9. Ironshore Pharmaceuticals Inc. $222 12 payments
  10. Bausch Health US, LLC $147 14 payments
  11. Other $554 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,314 262 payments
  2. Education $61 2 payments
Products named General payments · program years 2021–2025
  1. REXULTI Psychiatry $669 36 payments
  2. REXULTI Psychiatry $663 45 payments
  3. ABILIFY MAINTENA $479 32 payments
  4. CAPLYTA $403 27 payments
  5. VRAYLAR $362 23 payments
  6. Azstarys $345 21 payments
  7. Auvelity $306 15 payments
  8. LYBALVI Cns $303 13 payments
  9. TRINTELLIX $243 14 payments
  10. LYBALVI Cns $188 8 payments
  11. Other $1,984 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,095

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$56,183

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

21.4%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 19 $28,777
Vraylar Cariprazine Hcl Brand 13 $7,895
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 46 $3,532
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 41 $2,137
Lamotrigine Generic 167 $2,116
Trazodone Hcl Generic 76 $1,431
Buspirone Hcl Generic 75 $1,177
Duloxetine Hcl Generic 60 $1,122
Aripiprazole Generic 41 $1,060
Sertraline Hcl Generic 103 $960

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $298
  • Otsuka America Pharmaceutical, Inc. $101
$399 19 —
CAPLYTA
  • ITI, Inc. $170
$170 — —
Auvelity
  • Axsome Therapeutics, Inc. $157
$157 — —
Azstarys
  • Corium, Inc. $133
$133 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $131
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record